News
SRPT
130.23
+1.54%
1.98
Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?
NASDAQ · 2d ago
Weekly Report: what happened at SRPT last week (0318-0322)?
Weekly Report · 3d ago
We Might See A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Soon
Sarepta Therapeutics, Inc. Focuses on the discovery and development of RNA-targeted therapeutics for the treatment of rare diseases. The company posted a loss of US$536m in its most recent financial year. Consensus from 19 of the American Biotechs analysts is that the company is on the verge of breakeven. Analysts expect the company to grow 42% year-on-year. SareptaTherapeutics is expected to be profitable by 2024.
Simply Wall St · 5d ago
Oppenheimer Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
TipRanks · 6d ago
S&P 500 Futures Climb In Premarket Trading; Lululemon Athletica, Nike Lag
U.S. Stock markets are set to open in two hours. FedEx Corp. Was up 12.1% in pre-market trading. S&P 500 futures were up 0.10%, with futures for the Dow Jones Industrial Average rising 0.11%. Stocks in Asia were mixed overnight. In commodities news, Brent crude oil futures were down 0.05%. Bitcoin slipped 0.77%.
Barron‘s · 6d ago
FDA greenlights Italfarmaco's drug for rare muscular dystrophy
U.S. FDA approves privately held Italfarmaco Group's drug to treat Duchenne muscular dystrophy. DMD is an inherited muscle-wasting disorder. FDA greenlights drug for rare muscular dystrophy, a muscle-eating disorder.
Reuters · 6d ago
Weekly Report: what happened at SRPT last week (0311-0315)?
Weekly Report · 03/18 09:21
Deals Are Coming Back. These 8 Companies Are Buyout Candidates.
Companies in the U.S. Have announced $388.2 billion of M&A this year, 63% higher than at this point last year. Last year, $1.37 trillion of deals were made in the United States. Management teams are now more confident that buying new assets will produce strong returns. Smaller companies with low market caps could be buyout targets. Morgan Stanley offers criteria to find the companies.
Barron‘s · 03/15 06:15
Piper Sandler upgrades Solid Biosciences to overweight
Healthcare Piper Sandler upgrades Solid Biosciences to overweight. Analyst cites upcoming data for its Duchenne muscular dystrophy gene therapy candidate SGT-003. The investment firm set its price target for the stock at $20. Pied Sandler says the company will be ready to enter the registration-enabling phase in 2025.
Seeking Alpha · 03/13 20:42
Catalyst announces US launch of Duchenne drug Agamree
Healthcare Catalyst announces US launch of Duchenne drug Agamree in the U.S. For the treatment of muscular dystrophy. The therapy was approved by the FDA in October. Other drugmakers with DMD therapies in development or on the market include Roche and Pfizer.
Seeking Alpha · 03/13 17:46
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
New clinical data from Regenxbio shows a gene therapy for Duchenne muscular dystrophy is making headway. Sarepta Therapeutics could have a serious new competitor on the horizon. The company is developing a drug to treat the disease. But the company may not be a serious threat to Sarepta's business.
The Motley Fool · 03/13 12:00
Sarepta Therapeutics: A Strong Buy on Promising Drug Outlook and Strategic Growth Potential
TipRanks · 03/13 09:45
Buy Rating for Sarepta Therapeutics Amidst Promising Developments and Strategic Partnerships
TipRanks · 03/13 06:35
Sarepta Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 03/12 02:04
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
RegenXBIO Inc. (NASDAQ:RGNX) has made remarkable progress in advancing its pipeline of gene therapies. The company has reported positive interim results from a study using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. It is also on track to file a BLA for its MPS II program in 2024. The odds of the company reaching the finish line have been upgraded from buy to strong buy. Its NAV Technology Platform is building upon next-generation AAV vectors to enhance efficacy.
Seeking Alpha · 03/11 15:53
S&P 500 Futures Drop In Premarket Trading; MicroStrategy, Coinbase Global Lead
U.S. Stock markets are set to open in two hours. Bitcoin rose 3.00% to $71,619 in pre-market trading. Stocks in Asia were mixed overnight. Brent crude oil futures were down 0.34% in commodities news. The S&P 500 and the Dow are down in early trading.
Barron‘s · 03/11 11:31
Weekly Report: what happened at SRPT last week (0304-0308)?
Weekly Report · 03/11 09:21
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
REGENXBIO Inc is a company focused on developing gene therapies. RBC Capital Markets upgraded the company's stock to overweight. The company recently reported positive interim data in a Duchenne muscular dystrophy trial of RGX-202 in patients with the disease.
Benzinga · 03/08 18:43
Regenxbio raised to Buy at RBC on pivot to Duchenne
Healthcare Regenxbio raised to Buy at RBC on pivot to Duchenne muscular dystrophy. RBC Capital Markets upgraded the gene therapy developer to Outperform from Sector Perform. The upgrade comes days after the company updated interim data from its Phase 1/2 trial for gene therapy candidate RGX-202.
Seeking Alpha · 03/08 14:23
More
Webull provides a variety of real-time SRPT stock news. You can receive the latest news about Sarepta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.